{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:26:33Z","timestamp":1770683193794,"version":"3.49.0"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":3042,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2000,10]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>Apoptosis and mitochondrial dysfunction are thought to be involved in the aetiology of neurodegenerative diseases. We have tested an orally active anti\u2010apoptotic molecule (CGP 3466B) that binds to glyceraldehyde\u20103\u2010phosphate dehydrogenase (GAPDH) in an animal model with motoneuron degeneration, i.e. a mouse mutant with progressive motor neuronopathy (pmn).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>In <jats:italic>pmn\/pmn<\/jats:italic> mice, CGP 3466B was administered orally (10\u2013100\u2003nmol\u2003kg<jats:sup>\u22121<\/jats:sup>) at the onset of the clinical symptoms (2 weeks after birth). CGP 3466B slowed disease progression as determined by a 57% increase in life\u2010span, preservation of body weight and motor performance.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>This improvement was accompanied by a decreased loss of motoneurons and motoneuron fibres as well as an increase in retrograde transport. Electron microscopic analysis showed that CGP 3466B protects mitochondria which appear to be selectively disrupted in the motoneurons of <jats:italic>pmn\/pmn<\/jats:italic> mice.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The data support evaluation of CGP 3466B as a potential treatment for motor neuron disease.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2000) <jats:bold>131<\/jats:bold>, 721\u2013728; doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0703633\">10.1038\/sj.bjp.0703633<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0703633","type":"journal-article","created":{"date-parts":[[2005,1,28]],"date-time":"2005-01-28T20:58:37Z","timestamp":1106945917000},"page":"721-728","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["An orally active anti\u2010apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease"],"prefix":"10.1111","volume":"131","author":[{"given":"Y","family":"Sagot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Toni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Perrelet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Lurot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Rixner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Mattenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P C","family":"Waldmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A C","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-4388(96)80100-0"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80272-X"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1995.1223"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(94)90162-7"},{"key":"e_1_2_7_6_1","first-page":"2","article-title":"Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde\u20103\u2010phosphate dehydrogenase to a dimer","volume":"57","author":"CARLILE G.W.","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.19.10824"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701885"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4695(19980615)35:4<361::AID-NEU3>3.0.CO;2-X"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390203"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8209258"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1996.66030928.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1994.tb12073.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-09-03241.1998"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.10.5821"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1146\/annurev.physiol.60.1.619","article-title":"The mitochondrial death\/life regulator in apoptosis and necrosis","volume":"60","author":"KROEMER G.","year":"1998","journal-title":"Ann. Rev. Physiol."},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1997.4026"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-2728(98)00112-1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-01-00104.1998"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-2728(98)00124-8"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(98)00049-6"},{"key":"e_1_2_7_22_1","first-page":"S6C","article-title":"CGP3466 prevents neuronal death in models of ischemia and seizure in vivo","volume":"70","author":"PATERSON I.A.","year":"1998","journal-title":"J. Neurochem."},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1998.70020515.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.3.689"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-4388(96)80103-6"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.15-11-07727.1995"},{"key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1523\/JNEUROSCI.18-03-01132.1998","article-title":"Differential effects of neurotrophic factors on motoneuron retrograde labeling in a murine model of motoneuron disease","volume":"18","author":"SAGOT Y.","year":"1998","journal-title":"J. Neurosci."},{"key":"e_1_2_7_28_1","first-page":"2335","article-title":"GDNF cannot prevent nerve degeneration in an animal model of motoneuron disease","volume":"16","author":"SAGOT Y.","year":"1996","journal-title":"J. Neurosci."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1995.tb01122.x"},{"key":"e_1_2_7_30_1","first-page":"330","article-title":"Clinical and molecular aspects of motoneurone diseases: animal models, neurotrophic factors and Bcl\u20102 oncoprotein","volume":"18","author":"SAGOT Y.","year":"1997","journal-title":"TiPS"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.21.11669"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-18-06999.1997"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-199708000-00004"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.6_Suppl_3.171S"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012525445-8\/50014-X"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-03-00932.1998"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)03181-9"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90181-G"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201989"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.139.5.1307"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0703633","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0703633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0703633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T14:13:43Z","timestamp":1698588823000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0703633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,10]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,10]]}},"alternative-id":["10.1038\/sj.bjp.0703633"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0703633","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,10]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}